Diketopiperazines, natural products found in bacteria, fungi, marine sponges, gorgonian and red algae, are cyclic dipeptides possessing relatively simple and rigid structures with chiral nature and various side chains. The compounds in this structure class have been known to possess diverse bioactivities including antibiotic activity, anti-cancer activity, neuroprotective activity, and anti-inflammatory activity. The expression of secretory group IIA phospholipase A2 (sPLA2-IIA) is enhanced by development of inflammatory disorders. Aim of this study is to determine the effects of diketopiperazines on the secretion and activity of sPLA2-IIA by lipopolysaccharide (LPS) in human umbilical vein endothelial cells (HUVECs). To do this, sPLA2-IIA expression was induced in the LPS-stimulated HUVECs and mice to evaluate the effect of diketopiperazines. Results showed that diketopiperazines remarkably suppressed the LPS-mediated protein expression and activity of sPLA2-IIA via inhibition of phosphorylation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. These results demonstrated that diketopiperazines might play an important role in the modulation of sPLA2-IIA expression and activity in response to the inflammatory diseases.
A superfamily of enzymes phospholipases A2 (PLA2) hydrolyzes the ester bond at sn-2 position of phosphoglycerides to release a free fatty acid and lysophospholipids [1] [2] . PLA2 is consisted with four individual groups according to the molecular weight and Ca 2+ -dependence such as secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2), Ca 2+ -dependent PLA2, and lipoprotein-associated PLA2 [1] [2] . Among them, sPLA2 is triggered with the various inflammatory diseases containing rheumatoid arthritis, sepsis, bowel disease, respiratory distress syndrome, and so on [3] . Especially, the patients suffered from sepsis, septic shock, and polytrauma showed the high levels of sPLA2-IIA [4] [5] [6] [7] [8] [9] . In the previous reports, the secretory group IIA phospholipase A2 (sPLA2 IIA) has been thought as a regulator for variety of biological mechanisms in mammalian cells involved to coagulation, signal transduction, apoptosis, remodeling of cellular membranes, and host defense [10] [11] [12] .
Diketopiperazine is a natural products found from bacteria, fungi, marine sponges, gorgonian and red algae [13] .They are cyclic dipeptides possessing relatively simple and rigid structures with chiral nature and various side chains. The compounds in this structure class have been known to possess diverse bioactivities including antibiotic activity, anti-cancer activity, neuroprotective activity, and anti-inflammatory activity [14] . In the course of screening for the expression and activity of sPLA2-IIA from natural products, the ethyl acetate extracts of two independently fermented bacterial strains derived from marine sources showed potent inhibition on the expression and activity of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Repeated chromatographic separation gave three of diketopiperazines, cyclo(l-Pro-d-Val) (1), cyclo(l-Pro-l-Tyr) (2) and cyclo(l-Pro-d-Leu) (3), and these proline-containing compounds have been reported from the fermented bacterial strains [15] , fungal strains [16] , and the other macroorganisms [17] . Although several of diketopiperazines have been reported to have diverse biological activities including antibiotic and anti-inflammatory activities [14] , the effects of 1-3 on the expression and activity of sPLA2-IIA have not yet been studied. Therefore, we investigated the effect 1-3 on sPLA-IIA using in vitro and in vivo system. Compounds 1 and 2 were isolated as white amorphous solid from the extract of Bacillus sp. HC001 culture media by ethyl acetate extraction. Compound 3 was isolated as white amorphous solid from the ethyl acetate extract of the cultured Piscicoccus sp. 12L081.
Compounds 1-3 ( Figure 1 ) were identified to be cyclo(l-Pro-d-Val), cyclo(l-Pro-l-Tyr) (2) and cyclo(l-Pro-d-Leu) (3), respectively, by the analyses of spectroscopic data including 1 H and 13 C NMR data, LC-ESI-MS data and specific rotation values [11, 17] .
When the various concentrations of LPS were treated to HUVECs for 24 h, the sPLA2-IIA levels in the cell culture media were peaked from 100 ng/mL LPS (data not shown). In addition, this trend was also shown in the serum-free culture media supplemented with 0.2% BSA, therefore, the possibility of which the effect of LPS on sPLA2-II2 was resulted by the serum content was excluded. Thus, 100 ng/mL LPS was used for the subsequent experiments to stimulate the endothelial cells.
As shown in Figure 2A , 1-3 significantly suppressed the LPSinduced sPLA2-IIA expression of HUVECs in a concentrationdependent manner. In addition, the enhanced activity of sPLA2-IIA was also inhibited by 1-3 treatment (IC 50 = 4.38 μM for 1; 4.52 μM for 2; 4.53 μM for 3, Fig. 2B ). From these data, we knew that 1-3 had a remarkable effect on sPLA2-IIA-related inflammatory mechanisms stimulated by LPS. To prove the effect of 1-3 in vivo, mice were induced endotoxemia and sepsis via LPS injection and CLP, respectively. After induction of sepsis, mice showed the clinical signs such as shivering, weakness, and bristled hair. When the mice were administered with 1(1.93 or 3.93 mg/mouse), 2(2.60 or 5.21 mg/mouse), and 3(2.10 or 4.20 mg/mouse), the sPLA2-IIA expression mediated by LPS and CLP were significantly decreased in concentration-dependent manner ( Figure 3A and B) . Since, the average circulating blood volume for mice is 72 mL/kg [18] and the average weight of used mouse is 27 g, and the average blood volume is 2 mL, the amounts of each compound in peripheral blood were estimated to 5 and 10 mM, respectively. LPS-induced phosphorylation of ERK 1/2 and cPLA2α in HUVECs were attenuated by 10 μM of 1-3 ( Figure 4A ). Thus, the roles of ERK 1/2 and cPLA2α were tested by activation in 100 ng/mL LPSmediated sPLA2-IIA expression in HUVECs. When HUVECs were pre-treated with 5 μM U0126 or 20 μM AACO before LPS stimulation, sPLA2-IIA expression were significantly reduced compared to the cells treated with LPS only ( Figure 4B ). These data indicated that 100 ng/mL LPS-induced the activation of ERK 1/2 and cPLA2α can regulate the expression of sPLA-IIA, and the inhibitory effects of 1-3 on LPS-mediated sPLA-IIA production were originated from the suppressed phosphorylation of ERK 1/2 and cPLA2α.
The involvement of sPLA 2 -IIA in inflammatory diseases in humans is well documented such as sepsis, septic shock and polytrauma and it is well correlated with the severity of inflammation diseases [4] [5] [6] [7] [8] [9] . The expression level of sPLA 2 -IIA is markedly induced by proinflammatory mediators and downregulated by anti-inflammatory cytokines in a variety of cells and tissues in mammalians [5, 7, 9] . Therefore, the sPLA 2 -IIA is thought to associate with the initiation and multiplication of inflammatory reactions. In supporting this, the inflammatory diseases are attenuated by sPLA 2 -IIA inhibitors [19] [20] [21] , and in turn, purified sPLA 2 -IIA aggravates these responses when injected into inflamed tissues [22] . Thus, sPLA 2 -IIA seems to be pertinent to in the pathophysiology of various inflammatory diseases. In this study, we demonstrated that the expression level and activity of sPLA2-IIA were significantly inhibited by 1-3 in vitro and in vivo (Figure 2 and 3) , indicating the possible use of 1-3 as anti-inflammatory reagent candidates against sepsis, septic shock and polytrauma.
Despite specific inhibitors were used to oppose the abnormal production of sPLA 2 -IIA, it was ineffective to improve the clinical outcome for the patients with severe sepsis or rheumatoid arthritis [20, 23] . Therefore, improved approach needed for the cure of severe inflammatory diseases. Noting that the abnormal production or secretion of sPLA 2 -IIA was suppressed by 1-3, it may be one of the candidates for the inhibition of sPLA 2 -IIA expression. In this perspective1-3 could be of special interest since in this study 1-3 showed the inhibitory effect of sPLA 2 -IIA expression.
Experimental
Reagents: LPS, an ERK 1/2 inhibitor U1026, and a cPLA2α inhibitor arachidonyltrifluoromethyl ketone (AACO) were obtained from Sigma (St. Louis, MO, USA). sPLA2-IIA from GenWay Biotech Inc. (San Diego, CA, USA) was also used.
Microbial Isolation and Identification:
Bacillus sp. HC001 was obtained from marine sediments from Jeju Island, South Korea, in 2013. The collected sediments were dried under air flow for 1 day on a clean bench. The dried sediments were plated on the SYP SW agar media (soluble starch, 10 g/L; yeast extract, 4 g/L; peptone 2 g/L; agar 16 g/L; sterilized seawater 1 L) and the isolation plate was incubated at 27°C for two months. A yellow colored bacterial colony (HC001) was picked and a pure bacterial strain was obtained. The bacterial strain HC001 was identified as Bacillus sp. based on 16S rDNA sequence analysis (99.79%, similarity to Bacillus amyloliquefaciens strain Lx-11). Another bacterial strain (12L081) was isolated from a marine sponge collected from the coastal area of Seongsan, Jeju Island in 2012. A collected marine sponge was dried and powdered. The powdered sample was plated on SYP agar media. The plate was incubated for two months and a bright yellow colored bacterial strain (12L081) was isolated. The strain was identified to be Piscicoccus sp. based on the 16S rDNA sequence similarity (99.42%) to Piscicoccus intestinalis.
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Isolation of Compounds 1-3:
Each bacterial strain was inoculated in 35 L of SYP SW media (soluble starch, 10 g/L; yeast extract, 4 g/L; peptone 2 g/L; sterilized seawater 1 L) at 25°C for 7 days at 150 rpm. The cultured media of each strain (35 L) was extracted with EtOAc twice (35 L × 2) and the organic layer was concentrated in vacuo to give crude extracts (1.9 g for Bacillus sp. HC001 strain; 2.7 g for Piscicoccus sp. 12L081 strain). The extract of Bacillus sp. HC001 was subjected to VLC for fractionation. A portion of fraction E (eluting with CH 2 Cl 2 :MeOH=10:1) was further separated using preparative RP-HPLC (Phenomenex Luna 10μ C18(2) 100Å, 250 × 21.20 mm, 10 μm, 6 mL/min, 20% CH 3 CN in H 2 O) to afford compound 1 (2.5 mg) and compound 2 (1.6 mg). The extract of the culture media of Piscicoccus sp. 12L081 was also subjected to VLC and the fraction D (eluting with CH 2 Cl 2 :MeOH=20:1) was further purified by using preparative RP-HPLC (Phenomenex Luna 10μ C18(2) 100Å, 250 × 21.20 mm, 10 μm, 6 mL/min, 17% CH 3 CN in H 2 O) to yield 6.6 mg of compound 3. The structures of 1-3 were confirmed by the comparison of spectroscopic data [17, [24] [25] [26] .
Spectroscopic Data Acquisition:
Optical rotations were measured on a JASCO DIP-1000 polarimeter. NMR spectra were recorded with CD 3 OD (δ C 49.0, δ H 3.31), CDCl 3 (δ C 77.2, δ H 7.26), DMSOd 6 (δ C 39.5, δ H 2.50) on a Brucker 250 MHz spectrometer (250 and 63 MHz for 1 H and 13 C NMR, respectively). ESIMS spectra were obtained on an Agilent LC-MS 1260 infinity and 6120 quadrupole mass spectrometer.
Cell Culture: Primary HUVECs obtained from Cambrex Bio Science (Charles City, IA, USA) were maintained as previously described [27] [28] [29] [30] [31] [32] [33] [34] . For all experiments, HUVECs were used at passages from 3 to 5.
Animals and Husbandry:
Six to seven week-old male ICR mice (the average of body weight, 27 g) were obtained from Orient Bio Co. (Sungnam, Korea) and used after acclimatization period for 12 days. The five mice per a polycarbonate cage were cared with 12:12 h light/dark cycle and controlled humidity (RH, 40 -45%) at 20 -25°C. Mice received a normal pellet diet and water ad libitum. All animal experiments were performed according to the 'Guidelines for the Care and Use of Laboratory Animals' by Kyungpook National University (KNU2012-13).
Cecal Ligation and Puncture (CLP):
Before sepsis induction, mice were anesthetized with 2% isoflurane (JW Pharmaceutical, Seoul, Korea) in oxygen using a small rodent gas anesthesia machine (RC2, Vetequip, Pleasanton, CA, USA). The CLP-induced sepsis model was induced as previous literature [28] . To expose the cecum and adjoining intestine, a 2 cm midline incision was made. Then, the cecum was tightly ligated with 3-0 silk suture at 5 mm from the cecal tip, and punctured using a 22 gauge needle [35] . It was gently squeezed to extrude a small amount of feces from the perforation site and returned to peritoneal cavity followed by the 4-0 silk suture for laparotomy site. For sham control mice, the cecum was exposed without ligation and puncture, then returned to the abdominal cavity. For this experiment, the protocol was authorized by the Animal Care Committee at Kyungpook National University (IRB No. KNU 2012-13).
Measurement of sPLA2-IIA Protein Expression: The primary
HUVECs were pre-incubated with 1-3 for 6 h, and 5 μM U1026 or 20 μM AACO for 2 h, respectively. Then, the serum-free media for a control or 100 ng/mL LPS were treated to the cells for 24 h. On the other hand, 15 mg/kg LPS-treated mice by intraperitoneal (i.p.) injection or CLP-operated mice were administered with 1-3 for in vivo study. The plasma was prepared after 2 days. For detection of sPLA2-IIA in the cell culture supernatants, the enzyme-liked immunosorbent assay (ELISA) was performed using a commercial kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's instruction. Briefly, the diluted media or mouse plasma was applied to each well of a plate. After plate washing, the acetylcholinesterase-sPLA2-Fab´ conjugate was treated. Then, Ellman's reagent was added and the color development resulted by the acetylcholinesterase-catalyzed reaction was measured at 412 nm using a microplate reader (Tecan, Männedorf, Switzerland). The sPLA2-IIA concentration was estimated based on a standard curve of recombinant sPLA2-IIA.
sPLA2-IIA Activity Assay:
To measure the sPLA2-IIA activity, 1palmitoyl-2-[12-[7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sn-glycero-3-phospho-ethanolamine (NBD-PE; Avanti Polar Lipids, Alabaster, AL, USA) was used as a substrate [36] . The reaction mixture (100 μL) which is consisted with 50 mMTris-HCl (pH 8.0), 123 μM NBD-PE, 2 mM Ca2 + , and the indicated amounts of sPLA2-IIA was incubated at 30°C for 30 min with or without 1-3.
Western Blotting: The collected protein was quantified using bovine serum albumin (BSA) protein assay kit and equilibrated. The protein was applied to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 10% acrylamide gels, and transferred to nitrocellulose membranes. Membranes were blocked at room temperature (RT) for 1 h with 0.1% Tween 20 in Trisbuffered saline (TBST, pH 7.4) supplemented with 5% non-fat milk followed by the reaction with primary antibodies against ERK 1/2, phospho-ERK 1/2, cPLA2a, and phospho-cPLA2 at 4°C overnight. After membrane washing with TBST, the secondary antibodies were treated to membranes at RT for 1 h. The blots were detected by enhanced chemiluminescence (EMD Millipore, Billerica, MA, USA) and the densities of protein blots were analyzed using ImageJ Gel Analysis software.
Statistical Analysis:
All the experiments were performed three times at least. Data were shown as means ± SEM and the statistical differences were determined with p< 0.05 calculated by Student's t-test.
